Margaret Anderson, Managing Director
Deloitte
Charlene Banard, Head of Quality, Technical Operations
Shire
Richard Baron, Board of Directors
Aspire Bariatrics
Jeffrey Berkowitz, Former EVP
UnitedHealth Group
Liz Bywater, Ph.D., President
Bywater Consulting Group
Ron Cohen, M.D., President & CEO
Acorda Therapeutics
Laurie Cooke, CEO
Healthcare Businesswomen's Association (HBA)
Rich Daly, Chairman & CEO
Neuralstem
Raúl Díaz, Plant Manager, MSD Pharmaceutical Operations
Merck, Mexico
Tom Dilenge, President, Advocacy, Law & Public Policy Division
Biotechnology Innovation Organization
Tim Garnett, M.D., CMO & SVP of Medicines Development
Eli Lilly
Anu Hans, VP & CPO Enterprise Supply Chain
J&J
Fred Hassan, Managing Director
Warburg Pincus
Paul Hastings, Chairman & CEO
OncoMed
John Hubbard, Ph.D., Board Member
Agile Therapeutics
Maik Jornitz, CEO
G-CON Manufacturing
Mitchell Katz, Ph.D., Head of Medical Research & Drug Safety Operations
Purdue Pharma
Mary Rose Keller, VP, Clinical Operations
Heron Therapeutics
Rachel King, CEO
GlycoMimetics
Suresh Kumar, Former EVP External Affairs
Sanofi
John LaMattina, Ph.D., Sr. Partner
PureTech Ventures
Craig Lipset, Head of Clinical Innovation, Global Product Development
Pfizer
Sandy Macrae, Ph.D., President & CEO
Sangamo Therapeutics
Ken Moch, President & CEO
Cognition Therapeutics
Bernard Munos, Founder
InnoThink Center for Research in Biomedical Innovation
Carol Nacy, Ph.D., CEO
Sequella
Francois Nader, M.D., Chairman of the Board
Acceleron Pharma
Sesha Neervannan, Ph.D., SVP Pharmaceutical Development
Allergan
Mark Petrich, Ph.D., PE, Director, Single-Use Systems Engineering
Merck
Sandra Poole, Former EVP, Technical & Commercial Operations
ImmunoGen
Dennis Purcell, Founder & Sr. Advisor
Aisling Capital
David Pyott, Chairman of the Board
Bioniz Therapeutics
Chandra Ramanathan, Ph.D., MBA, VP & Head, East Coast Innovation Center
Bayer
Stephen Rapundalo, Ph.D., President & CEO
MichBio
John Reynders, Ph.D., VP, Data Sciences, Genomics, & Bioinformatics
Alexion Pharmaceuticals
James Robinson
Independent Manufacturing Consultant
Tomasz Sablinski,M.D., Ph.D., Cofounder & CEO
Transparency Life Sciences
Chhaya Shah, SVP Technical Operations
Synergy Pharmaceuticals
Andrew Skibo, EVP Operations
MedImmune RVP, AstraZeneca
Jason Urban, Ph.D., Sr. Director, Business Operational Excellence
Celgene
Leslie Williams, Founder, President & CEO
ImmusanT

IN THIS MONTH'S ISSUE

  • Trump Surprises: 340B Reform And Pharmaceutical Exec For HHS

    Policymakers recently have focused on the 340B program as its size increased. Whole cottage industries have been created that instruct how hospitals and contract pharmacies can profit from the loose regulations, to the point that the drug industry can no longer overlook the market inefficiencies Yet despite several oversight hearings by the House Energy & Commerce Committee, Congress could not come to a consensus on how to reform it.

  • 2018: The Year Of Biosimilar Commercialization Wins Or Woes?

    We reached out to eight experts from biosimilar companies and consulting firms to see which topics they’ve been watching closely throughout 2017 and how they expect these trends will evolve and challenge the industry in 2018.

  • Virtual And Variable: Two Visions For Biopharma Outsourcing In 2018

    Deborah Dunsire, CEO of XTuit Pharmaceuticals; and Robert Discordia, executive director, global product development & supply procurement for Bristol-Myers Squibb discuss new approaches to external partnerships in pharma.

  • Why All The Talk About Real-World Evidence?

    In 2017, real-world evidence (RWE) became the topic everyone wanted to discuss. Several executives I have spoken to recently believe it will continue to grow in importance as we move into 2018 and beyond. But why the sudden interest in RWE?

  • 7 Medical Device Leaders Talk About What’s Next For Their Industry

    Seven industry experts answer questions related to the med device funding climate, which device segment will be getting all of the attention in 2018, and upcoming M&A activity related to med devices.

More From Current Issue

@LIFESCILEADER1

 EVENTS

Building An Effective GMP Training System: A Risk-Based Approach December 19, 2017
1pm-2:30pm EST, Online Training)
Price:  $299 - Includes Bonus Handouts!
Best Practices for Deviation Investigations: Cost-Effective Problem Correction January 8, 2018
1pm-2:30pm EDT, Online Training)
Price:  $299 - Includes Bonus Handouts!
Renovating Pharmaceutical Manufacturing Facilities for Aseptic Fill/Finish: Critical Planning, Execution & Compliance Tips January 10, 2018
1pm-2:30pm EST, Online Training)
Price:  $299 - Introductory Rate
EU vs. US GMP: Understanding Major Differences Post FDA/EMA Mutual Recognition Agreement January 16, 2018
1pm-2:30pm EST, Online Training)
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
CAPA and Root Cause Analysis Essentials Post ICH GCP E6 (R2) Addendum January 22, 2018
11am-12:30pm EST, Online Training)
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!